株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の癌免疫療法市場の予測:2024年

Global Cancer Immunotherapies Market to 2024 - Increased Uptake of Immune Checkpoint Inhibitors Driving Growth, Supported by a Large, Robust Pipeline

発行 GlobalData 商品コード 676510
出版日 ページ情報 英文 215 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.43円で換算しております。
Back to Top
世界の癌免疫療法市場の予測:2024年 Global Cancer Immunotherapies Market to 2024 - Increased Uptake of Immune Checkpoint Inhibitors Driving Growth, Supported by a Large, Robust Pipeline
出版日: 2018年07月01日 ページ情報: 英文 215 Pages
概要

世界の癌免疫療法市場における収益は、2017年の337億米ドルから2024年までに1,034億米ドルへ拡大すると予測され、17.4%のCAGR (年間複合成長率) が見込まれています。

当レポートでは、世界の癌免疫療法市場について調査し、市場収益の実績・予測・CAGR (複合年間成長率) 、成長の促進要因、主要企業の市場シェア、市場投入が見込まれる新規承認薬と治験の後期段階にある薬剤、治験情勢、および市場・パイプライン企業の情勢などについて分析しています。

第1章 目次

第2章 イントロダクション

  • 治療領域のイントロダクション
  • 主な症状・症候の概要
    • 乳癌
    • 白血病
    • リンパ腫
    • メラノーマ
    • 非小細胞肺癌
  • 診断
  • 病因・病態生理学
  • 疫学
  • 予後
  • 治療

第3章 主な上市製品

第4章 パイプライン情勢の評価

  • 概要
  • パイプライン開発状況
  • パイプラインにおける分子標的
  • 治験情勢
    • 失敗率
    • 期間
    • 規模
    • 累積治験規模
  • 開発パイプラインの後期段階にある薬剤

第5章 マルチシナリオ市場予測

  • 全体的な市場規模
  • ジェネリック医薬品の浸透
  • 収益予測:分子標的別
    • 免疫チェックポイントタンパク質
    • 腫瘍関連抗原
    • サイトカインシグナル伝達
    • HPV

第6章 企業分析・ポジショニング

  • 収益・市場シェア分析:企業別
  • 市場・パイプライン企業情勢

第7章 戦略統合

  • ライセンシング契約
  • 共同開発契約

第8章 付録

図表

List of Tables

  • Table 1: Cancer Immunotherapies Drugs Market, Global, Breast Cancer Histopathological and Molecular Classification, 2018
  • Table 2: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology of Key Indications, 2016
  • Table 3: Cancer Immunotherapies Drugs Market, US, Breast Cancer Stage at Diagnosis and Five-Year Relative Survival Rate (%), 2016
  • Table 4: Cancer Immunotherapies Drugs Market, US, Leukemia Subtype and Five-Year Survival Rates (%), 2016
  • Table 5: Cancer Immunotherapies Drugs Market, US, Lymphoma Subtype and Survival Rates (%), 2016
  • Table 6: Cancer Immunotherapies Drugs Market, US, Cutaneous Melanoma Stage and Survival Rates (%), 2016
  • Table 7: Cancer Immunotherapies Drugs Market, US, NSCLC Stage at Diagnosis and Five-Year Relative Survival (%), 2017
  • Table 8: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Revlimid, 2018
  • Table 9: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Opdivo, 2018
  • Table 10: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Keytruda, 2018
  • Table 11: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Tecentriq, 2018
  • Table 12: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Darzalex, 2018
  • Table 13: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications Imfinzi, 2018
  • Table 14: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Gardasil, 2018
  • Table 15: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Pomalyst, 2018
  • Table 16: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Yescarta, 2018
  • Table 17: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Gazyva, 2018
  • Table 18: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Yervoy, 2018
  • Table 19: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Rituxan, 2018
  • Table 20: Cancer Immunotherapies Drugs Market, Global, Approved Cancer Immunotherapies Indications for Kymriah, 2018
  • Table 21: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Key Products ($bn), 2017-2024
  • Table 22: Cancer Immunotherapies Drugs Market, Global, Forecast Revenue by Company, 2017-2024
  • Table 23: Cancer Immunotherapies Drugs Market, Global, Licensing Deals, 2006-2018
  • Table 24: Cancer Immunotherapies Drugs Market, Global, Co-development Deals, 2006-2018

List of Figures

  • Figure 1: Cancer Immunotherapies Drugs Market, Global, Frequency of Molecular Aberrations in Non-Small Cell Lung Cancer (%), 2018
  • Figure 2: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for Breast Cancer, 2016-2023
  • Figure 3: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for Leukemia, 2016-2023
  • Figure 4: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for Lymphoma, 2016-2023
  • Figure 5: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for Cutaneous Melanoma, 2016-2023
  • Figure 6: Cancer Immunotherapies Drugs Market, 7MM, Epidemiology Patterns for NSCLC, 2016-2023
  • Figure 7: Cancer Immunotherapies Drugs Market, Global, Key Marketed Products and Approved Indications, 2018
  • Figure 8: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Revlimid ($bn), 2006-2024
  • Figure 9: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Opdivo ($bn), 2014-2024
  • Figure 10: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Keytruda ($bn), 2014-2024
  • Figure 11: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Tecentriq ($bn), 2016-2024
  • Figure 12: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Darzalex ($bn), 2015-2024
  • Figure 13: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Imfinzi ($bn), 2017-2024
  • Figure 14: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Gardasil ($bn), 2006-2024
  • Figure 15: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Pomalyst ($bn), 2013-2024
  • Figure 16: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Yescarta ($bn), 2018-2024
  • Figure 17: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Gazyva ($bn), 2013-2024
  • Figure 18: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Yervoy ($bn), 2011-2024
  • Figure 19: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Rituxan ($bn), 2006-2024
  • Figure 20: Cancer Immunotherapies Drugs Market, Global, Annual Revenue for Kymriah ($bn), 2017-2024
  • Figure 21: Cancer Immunotherapies Drugs Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2018
  • Figure 22: Cancer Immunotherapies Drugs Market, Global, Cancer Immunotherapies Pipeline by Stage of Development, Molecule Type and Program Type, 2018
  • Figure 23: Cancer Immunotherapies Drugs Market, Global, Pipeline for Key Indications by Stage of Development, 2018
  • Figure 24: Cancer Immunotherapies Drugs Market, Global, Pipeline for Key Indications by Molecule Type, 2018
  • Figure 25: Cancer Immunotherapies Drugs Market, Global, Cancer Immunotherapies Pipeline by Molecular Target, 2018
  • Figure 26: Cancer Immunotherapies Drugs Market, Global, Pipeline for Key Indications by Molecular Target, 2018
  • Figure 27: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rate by Stage of Development (%), 2006-2018
  • Figure 28: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2018
  • Figure 29: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2018
  • Figure 30: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Failure Rates and Overall Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2018
  • Figure 31: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Duration by Stage of Development (months), 2006-2018
  • Figure 32: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2018
  • Figure 33: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2018
  • Figure 34: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2018
  • Figure 35: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2018
  • Figure 36: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2018
  • Figure 37: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2018
  • Figure 38: Cancer Immunotherapies Drugs Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2018
  • Figure 39: Cancer Immunotherapies Drugs Market, Global, Clinical Program Size by Stage of Development (participants), 2006-2018
  • Figure 40: Cancer Immunotherapies Drugs Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2018
  • Figure 41: Cancer Immunotherapies Drugs Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2018
  • Figure 42: Cancer Immunotherapies Drugs Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2018
  • Figure 43: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Lisocabtagene maraleucel ($m), 2018-2024
  • Figure 44: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Durvalumab plus Tremelimumab ($m), 2018-2024
  • Figure 45: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Tremelimumab ($m), 2018-2024
  • Figure 46: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Cemiplimab ($m), 2019-2024
  • Figure 47: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Epacadostat ($bn), 2020-2024
  • Figure 48: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Axalimogene filolisbac ($m), 2020-2024
  • Figure 49: Cancer Immunotherapies Drugs Market, Global, Market Size ($bn), 2017-2024
  • Figure 50: Cancer Immunotherapies Drugs Market, Global, Key Products Market Share, 2017-2024
  • Figure 51: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Premium and Generic Products ($bn), 2017-2024
  • Figure 52: Cancer Immunotherapies Market, Global, Annual Revenue Forecast for Immune Checkpoint Proteins ($bn), 2017-2024
  • Figure 53: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Tumor Associated Antigens ($bn), 2017-2024
  • Figure 54: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for Cytokine Signaling ($bn), 2017-2024
  • Figure 55: Cancer Immunotherapies Drugs Market, Global, Annual Revenue Forecast for HPV Vaccines ($bn), 2017-2024
目次
Product Code: GBIHC479MR

Summary:

Cancer immunotherapy, which can predominantly be classed as a form of targeted therapy, drives an immune response against cancer cells. This may include stimulating a patient's immune system in a general way or aiding the identification of specific antigens associated with the cancer.

The interest in cancer immunotherapy development has been driven by the growing understanding of the immune system as a hallmark of cancer pathophysiology, particularly immune evasion of developing cancer cells. Overall, 3,863 products are being actively developed in the cancer immunotherapy pipeline, approximately half of the overall oncology pipeline.

The report focuses on the key indications of breast cancer, leukemia, lymphoma, melanoma and non-small cell lung cancer, these indications are the largest in terms of size, with 448, 526, 456, 415 and 374 in active development, respectively. The pipeline is dominated mAbs, cell therapies, small molecules and cancer vaccines.

Scope:

  • Global revenue from the cancer immunotherapies market is forecast to increase from $33.7 billion in 2017 to $103.4 billion in 2024, at a compound annual growth rate of 17.4%. What is driving this growth?
  • The leading companies in terms of market share are Celgene, Merck & Co., Bristol-Myers Squibb and Roche. Which of these are forecast to experience the largest growth?
  • There are some key new approvals and late-stage products set to enter the market during the forecast period. Which impact will these drugs have on the market?
  • The market has been dominated by immune checkpoint inhibitors and drugs that target tumor associated antigens. To what extent will these classes of drugs and others dominate the market over the forecast period?
  • There are 3,863 cancer immunotherapy products in the pipeline. What molecular targets are most abundant in the pipeline and what role will pipeline product approvals play in market growth?
  • Cancer immunotherapy clinical trials have an overall attrition rate of around 96%, what can companies do to maximize their chance of success?

Reasons to buy:

  • Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug's mechanism of action.
  • Analyze the cancer immunotherapy pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target. This review also provides a detailed look at current cancer immunotherapies to provide an insight into the risk associated of attempting to bring pipeline products to market.
  • Predict growth in market size, with in-depth market forecasting from 2017 to 2024. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and certain patent expirations will influence market value.
  • Identify commercial opportunities in the cancer immunotherapies deals landscape by analyzing trends in licensing and co-development deals

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Therapy Area Introduction
  • 2.2. Overview of Key Indications and Symptoms
    • 2.2.1. Breast Cancer
    • 2.2.2. Leukemia
    • 2.2.3. Lymphoma
    • 2.2.4. Melanoma
    • 2.2.5. Non-Small Cell Lung Cancer
  • 2.3. Diagnosis
    • 2.3.1. Breast Cancer
    • 2.3.2. Leukemia
    • 2.3.3. Lymphoma
    • 2.3.4. Melanoma
    • 2.3.5. Non-Small Cell Lung Cancer
  • 2.4. Etiology and Pathophysiology
    • 2.4.1. Breast Cancer
    • 2.4.2. Leukemia
    • 2.4.3. Lymphoma
    • 2.4.4. Melanoma
    • 2.4.5. Non-Small Cell Lung Cancer
  • 2.5. Epidemiology
    • 2.5.1. Breast Cancer
    • 2.5.2. Leukemia
    • 2.5.3. Lymphoma
    • 2.5.4. Melanoma
    • 2.5.5. Non-Small Cell Lung Cancer
  • 2.6. Prognosis
    • 2.6.1. Breast Cancer
    • 2.6.2. Leukemia
    • 2.6.3. Lymphoma
    • 2.6.4. Melanoma
    • 2.6.5. Non-Small Cell Lung Cancer
  • 2.7. Treatment

3. Key Marketed Products

  • 3.1. Overview
  • 3.2. Revlimid (lenalidomide) - Celgene
  • 3.3. Opdivo (nivolumab) - Ono Pharma/Bristol-Myers Squibb
  • 3.4. Keytruda (pembrolizumab) - Merck & Co.
  • 3.5. Tecentriq (atezolizumab) - Roche
  • 3.6. Darzalex (daratumumab) - Johnson & Johnson
  • 3.7. Imfinzi (durvalumab) - AstraZeneca/Celgene
  • 3.8. Gardasil/Gardasil 9(human papillomavirus vaccine) - Merck & Co.
  • 3.9. Pomalyst/Imnovid (pomalidomide) - Celgene
  • 3.10. Yescarta (axicabtagene ciloleucel) - Gilead Sciences
  • 3.11. Gazyva (obinutuzumab) - Roche
  • 3.12. Yervoy (ipilimumab) - Bristol-Myers Squibb
  • 3.13. Rituxan (rituximab) - Roche/Biogen
  • 3.14. Kymriah (tisagenlecleucel) - Novartis

4. Pipeline Landscape Assessment

  • 4.1. Overview
  • 4.2. Pipeline Development Landscape
  • 4.3. Molecular Targets in the Pipeline
  • 4.4. Clinical Trials Landscape
    • 4.4.1. Clinical Trial Failure Rates
    • 4.4.2. Clinical Trial Duration
    • 4.4.3. Clinical Trial Size
    • 4.4.4. Cumulative Clinical Trial Size
  • 4.5. Late-Stage Drugs of the Developmental Pipeline
    • 4.5.1. Lisocabtagene maraleucel - Juno Therapeutics/Celgene
    • 4.5.2. Durvalumab plus Tremelimumab - AstraZeneca
    • 4.5.3. Tremelimumab - AstraZeneca
    • 4.5.4. Cemiplimab - Regeneron/Sanofi
    • 4.5.5. Epacadostat - Incyte Corp
    • 4.5.6. Axalimogene filolisbac - Advaxis

5. Multi-scenario Market Forecast to 2024

  • 5.1. Overall Market Size
  • 5.2. Generic Penetration
  • 5.3. Revenue Forecast by Molecular Target
    • 5.3.1. Immune Checkpoint Proteins
    • 5.3.2. Tumor Associated Antigens
    • 5.3.3. Cytokine Signaling
    • 5.3.4. HPV

6. Company Analysis and Positioning

  • 6.1. Revenue and Market Share Analysis by Company
    • 6.1.1. Celgene - Revlimid to Maintain Celgene's Position as Market Leader
    • 6.1.2. Merck & Co. - Keytruda Key to Cancer Immunotherapy Market Growth
    • 6.1.3. Bristol-Myers Squibb - Opdivo to Drive Revenue from Cancer Immunotherapies
    • 6.1.4. Roche - Strong Revenue from Tecentriq and Gazyva Set to Offset Loss from Rituxan
    • 6.1.5. AstraZeneca - Revenue from Imfinzi set to Drive Growth amid Growing Immunotherapy Presence
    • 6.1.6. Johnson & Johnson - Darzalex Key to Strong Growth
    • 6.1.7. Novartis - Diverse Cancer Immunotherapies Portfolio Contributes Small Portion to Overall Revenue
    • 6.1.8. AbbVie - Recent New Approvals to Result in AbbVie Becoming a Leading Player in 2024
    • 6.1.9. Gilead Sciences - Growth Driven by CAR-T Therapy Yescarta
    • 6.1.10. Amgen - Rituximab Biosimilar to Drive Growth for Amgen in a Portfolio with No Novel Blockbusters
  • 6.2. Market and Pipeline Company Landscape

7. Strategic Consolidations

  • 7.1. Licensing Deals
    • 7.1.1. Deals by Region, Deal Value and Year
    • 7.1.2. Deals by Indication and Deal Value
    • 7.1.3. Deals by Stage of Development and Deal Value
    • 7.1.4. Deals by Molecule Type, Molecular Target and Deal Value
    • 7.1.5. Table for Licensing Deals with Disclosed Deal Value
  • 7.2. Co-development Deals
    • 7.2.1. Deals by Region, Deal Value and Year
    • 7.2.2. Deals by Indication and Deal Value
    • 7.2.3. Deals by Stage of Development and Deal Value
    • 7.2.4. Deals by Molecule Type, Molecular Target and Deal Value
    • 7.2.5. Table for Co-development Deals with Disclosed Deal Value

8. Appendix

  • 8.1. References
  • 8.2. Figures of All Clinical Stage Pipeline Products
  • 8.3. Abbreviations
  • 8.4. Disease List
  • 8.5. Methodology
    • 8.5.1. Coverage
    • 8.5.2. Secondary Research
    • 8.5.3. Market Size and Revenue Forecasts
    • 8.5.4. Pipeline Analysis
    • 8.5.5. Competitive Landscape
  • 8.6. Contact Us
  • 8.7. Disclaimer
Back to Top